Explore Global Cutaneous Mastocytosis Market Forecast to 2018-2025
Summary:
In 2017, the global Cutaneous Mastocytosis market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.
Description:
This report focuses on the Global Cutaneous Mastocytosis Market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cutaneous Mastocytosis development in United States, Europe and China.
Mastocytosis is rare condition characterized by excessive accumulation of mast cells in the body tissues. Mast cells release large amounts of histamine in blood which leads to itchy skin, skin rash and hot flushes. These cells are found in skin and the lining of stomach and lungs. Mast cells accumulated in the skin is referred to as cutaneous mastocytosis. Usually affecting children, the most common symptoms of cutaneous mastocytosis is abnormal growth on the skin such as spots or blisters which can form a rash on the body. The World Health Organization (WHO) has classified cutaneous mastocytosis into three variants namely urticaria pigmentosa, diffuse cutaneous mastocytosis and solitary cutaneous mastocytosis. Besides these, there are two other forms of cutaneous mastocytosis namely nodular mastocytosis and telangiectasia macularis eruptive perstans (TMEP) which are currently under review as they are very rare form of condition.
Treatment for cutaneous mastocytosis mainly aims to relieve symptoms. Therefore, medications such as antihistamines, corticosteroids, proton pump inhibitors, immunomodulators and mast cell stabilizers. Cromolyn sodium oral solution is the only FDA approved medication for the treatment of mastocytosis. However, these products are often associated with undesired side effects including hypo pigmentation, acne, skin thinning and secondary infection. With limited evidence to support their long term safety, there is a huge opportunity for novel and effective therapies.
Request a sample of this report @ http://orbisresearch.com/contacts/request-sample/2316034
Mastocytosis is rare condition characterized by excessive accumulation of mast cells in the body tissues. Mast cells release large amounts of histamine in blood which leads to itchy skin, skin rash and hot flushes. These cells are found in skin and the lining of stomach and lungs. Mast cells accumulated in the skin is referred to as cutaneous mastocytosis. Usually affecting children, the most common symptoms of cutaneous mastocytosis is abnormal growth on the skin such as spots or blisters which can form a rash on the body. The World Health Organization (WHO) has classified cutaneous mastocytosis into three variants namely urticaria pigmentosa, diffuse cutaneous mastocytosis and solitary cutaneous mastocytosis. Besides these, there are two other forms of cutaneous mastocytosis namely nodular mastocytosis and telangiectasia macularis eruptive perstans (TMEP) which are currently under review as they are very rare form of condition.
Treatment for cutaneous mastocytosis mainly aims to relieve symptoms. Therefore, medications such as antihistamines, corticosteroids, proton pump inhibitors, immunomodulators and mast cell stabilizers. Cromolyn sodium oral solution is the only FDA approved medication for the treatment of mastocytosis. However, these products are often associated with undesired side effects including hypo pigmentation, acne, skin thinning and secondary infection. With limited evidence to support their long term safety, there is a huge opportunity for novel and effective therapies.
Request a sample of this report @ http://orbisresearch.com/contacts/request-sample/2316034
The key players covered in this study
AB Science
Novartis
BioCentury
Rarediseases
...
Market segment by Type, the product can be split into
Antihistamines
Corticosteroids
Proton Pump Inhibitors
Immunomodulators
Mast Cell Stabilizers
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
AB Science
Novartis
BioCentury
Rarediseases
...
Market segment by Type, the product can be split into
Antihistamines
Corticosteroids
Proton Pump Inhibitors
Immunomodulators
Mast Cell Stabilizers
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
If enquiry before buying this report @ http://orbisresearch.com/contacts/enquiry-before-buying/2316034
The study objectives of this report are:
To analyze global Cutaneous Mastocytosis status, future forecast, growth opportunity, key market and key players.
To present the Cutaneous Mastocytosis development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cutaneous Mastocytosis are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
To analyze global Cutaneous Mastocytosis status, future forecast, growth opportunity, key market and key players.
To present the Cutaneous Mastocytosis development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cutaneous Mastocytosis are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Comments
Post a Comment